Health Condition 1: null- Breast Cancer
Conditions
Interventions
None listed
Sponsors
DEPARTMENT OF BIOTECHNOLOGY
Eligibility
Inclusion criteria
Inclusion criteria: • Patients just diagnosed with breast cancer and planned for NACT. • Patients willing to provide written informed consent to participate in the study. • Patients whose tumors have any receptor phenotype. • Patients willing to receive the usual standard treatment in NACT setting
Exclusion criteria
Exclusion criteria: Patients with metastatic disease will not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of circulating biomarkers, specifically circulating tumor DNA (ctDNA), can provide information about the molecular characteristics of a patientâ??s tumor from a noninvasive blood draw, thus aiding the clinical management of this disease. To identify the biomarkers/ mutations derived from tumor tissue and subsequently use these markers (in a patient specific manner) to monitor therapy and relapse by quantifying the same mutations in peripheral blood.Timepoint: First biopsy and blood sample will be collected when the patients are planned for neoadjuvant chemotherapy. A repeat biopsy and blood sample will be collected from the same patients at the end of planned neoadjuvant chemotherapy at the time of surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| trying to identify the cluster of mutations occurring in the original tumor and their repetition in circulating tumor DNA. Identification of such biomarkers/ mutations derived from tumor tissue can be subsequently used to monitor therapy and relapse by quantifying the same mutations in peripheral blood. Timepoint: At timing of Neo adjuvant Chemotherapy. Second at the time of end of planned Neoadjuvant chemotherapy | — |
Countries
India
Contacts
Public ContactYogesh Kembhavi
Tata Memorial Centre
Outcome results
None listed